Literature DB >> 25888902

Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer.

Han-xiang Zhan1, Jian-wei Xu2, Lei Wang3, Guang-yong Zhang4, San-yuan Hu5.   

Abstract

BACKGROUND: The prognostic value of lymph node ratio (LNR) in pancreatic cancer remains controversial. In the current retrospective study, we assessed the value of LNR on predicting the survival of postoperative patients with pancreatic cancer.
METHODS: Medical records of patients who underwent pancreatic resection for pancreatic cancer in the department of general surgery, Qilu Hospital, Shandong University were reviewed retrospectively. Demographic, clinicopathological, tumor-specific data, and histopathological reports were collected. Univariate and multivariate survival analyses were performed.
RESULTS: A total of 83 patients with pancreatic cancer were collected. The mean number of examined LN was 8.2 ± 6.1 (0 to 26). Differential degree (low) (P = 0.019, hazard ratio (HR) = 2.276, 95% confidence interval (CI): 1.171 to 4.424) and LNR >0.2 (P = 0.018, HR = 2.685, 95% CI: 1.253 to 5.756) were independent adverse prognostic factors according to the multivariate survival analysis.
CONCLUSIONS: Our study indicated that LNR >0.2 was an independent adverse prognostic factor for pancreatic cancer, which may provide important information for prognostic assessment.

Entities:  

Mesh:

Year:  2015        PMID: 25888902      PMCID: PMC4380100          DOI: 10.1186/s12957-015-0510-0

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


Background

Pancreatic cancer is the fourth most frequent cause of cancer death in the United States with an overall 5-year survival rate of 5% [1]. Only 20% of cases can be resected when diagnosed. However, the 5-year survival rate is reported to range only between 15% and 25% [2]. Several factors are related to the prognostic outcome of patients with resection of pancreatic cancer, including tumor stage, histologic differentiation, tumor size, lymph node (LN) status, and resection margin status [3]. Of them, the prognostic value of LN status is always controversial. Several studies have demonstrated that LN metastasis is associated with poor prognosis of patients with pancreatic cancer, whereas some other studies have not observed the associations between LN metastasis and survival outcomes [4]. To assess the prognostic value of LN involvement better, the importance of lymph node ratio (LNR) has been highlighted, which is determined by dividing the total number of metastatic LNs by the total number of examined LNs [5]. Many studies have identified that LNR is a valuable prognostic factor in pancreatic cancer patients [5]. Nevertheless, its prognostic value in node-positive patients has not been shown in other studies [4]. Additionally, the cutoff values of LNR are inconsistent in different studies. LNR ≥0.2, 0.15, and 0.1 have all been reported as an independent poor predictive factor [6-9]. The current study aimed to assess the prognostic value of LNR in postoperative patients with pancreatic cancer.

Methods

This study has been approved by the ethics committee on scientific research of Shandong University, Qilu Hospital and has been performed in accordance with the ethical standards and according to the Declaration of Helsinki. Written informed consent was obtained from all subjects. A series of 83 patients who underwent resection for pancreatic cancer in the department of general surgery, Qilu Hospital, Shandong University was collected for analysis. Surgical procedures were conducted by senior surgeons. Medical records were reviewed retrospectively, and demographic, clinicopathological, tumor-specific data, and histopathological reports were collected. TNM staging was defined according to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Pancreatic Adenocarcinoma Version 1, 2014 (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp). Follow-up data were acquired from hospital records supplemented with telephone contact. The end point was overall survival. Survival time was calculated according to the date of death or as the time between the last follow-up date and the operation date. Statistical analysis was conducted using SPSS v.13.0 software (SPSS Inc., Chicago, IL, USA). A value of P < 0.05 was considered as statistically significant. Graphs were produced by GraphPad Prism 5 Software (GraphPad, San Diego, CA, USA). The Kaplan-Meier method and Cox regression were used for univariate and multivariate survival analyses, respectively.

Results

The clinicopathologic characteristics of patients

A total of 83 patients with pancreatic cancer were collected in the current study, including 53 males and 30 females, with an average age of 61.7 ± 10.7 (range 36 to 85) years old. The average size of the tumor diameter was 4.6 ± 2.23 cm (range 0.5 to 14 cm). The total number of examined LNs was range from 0 to 26, with a mean of 8.2 ± 6.1. The average follow-up was 26.9 months (median 15, range 1 to 87 months).

Univariate and multivariate survival analyses

The median survival was 20 months. The overall 1- and 3-year survival rates were 58.6% and 42.7%, respectively. Univariate survival analysis indicated that sex, differential degree, LN staging, TNM staging, LNR, and total number of examined LNs were potential prognostic factors (Table 1, Figure 1). Multivariate analysis demonstrated that differential degree (low) and LNR >0.2 were independent adverse prognostic factors (P = 0.019, hazard ratio (HR) = 2.276, 95% confidence interval (CI): 1.171 to 4.424; P = 0.018, HR = 2.685, 95% CI: 1.253 to 5.756) (Table 2).
Table 1

Univariate analysis of factors predictive of poor overall survival

Variables Case number ( n ) Univariate analysis
Overall survival (median ± SE, months) 1-year survival rate (%) P value
Sex0.041
  Male5315 ± 3.454.5
  Female3054 ± 11.065.9
Age(years old)0.718
  <655020 ± 9.662.0
  ≥653333 ± 15.953.2
Diabetes0.168
  No7423 ± 10.861.9
  Yes910 ± 1.533.3
Locations0.353
  Head5231 ± 14.863.1
  Body-tail3115 ± 4.751.6
Tumor size (cm)0.606
  ≤31220 ± 7.463.6
  >37023 ± 11.057.3
Differential degreea 0.039
  High/moderate5533 ± 12.866.3
  Low2210 ± 1.440.8
Tumor staging0.664
  T1/T26918 ± 9.657.3
  T3/T41423 ± 13.764.3
Lymph node staging0.041
  N05333 ± 14.169.0
  N13011 ± 1.339.7
TNM staging0.014
  I/II4154 ± 15.572.1
  III/IV4211 ± 3.145.5
Perineuronal invasion0.082
  No4843 ± 22.869.4
  Yes3511 ± 1.044.4
LNR0.001
  ≤0.26633 ± 13.669.0
  >0.2178 ± 1.113.8
Total number of examined LNs0.062
  <126115 ± 4.353.4
  ≥122255 ± Noneb 74.9

aThe differential degree of six cases is not recorded. bNone: if the number of censored data is more than 50% of the total, median survivals cannot be calculated by SPSS. LN, lymph node; SE, standard error.

Figure 1

Kaplan-Meier survival curves. Left panel, survival analysis based on LNR. Right panel, survival analysis based on the total number of examined LN. LN, lymph node; LNR, lymph node ratio.

Table 2

Multivariate analysis of factors predictive of poor overall survival

Variables Hazard ratio 95% confidence interval P value
LNR (>0.2)2.6851.253 to 5.7560.018
Differential degree (low)2.2761.171 to 4.4240.019
Sex (female)0.5780.298 to 1.1240.094
Lymph node staging (N1)0.7610.284 to 2.0420.717
TNM staging (III/IV)1.50.772 to 2.9140.229

LNR, lymph node ratio.

Univariate analysis of factors predictive of poor overall survival aThe differential degree of six cases is not recorded. bNone: if the number of censored data is more than 50% of the total, median survivals cannot be calculated by SPSS. LN, lymph node; SE, standard error. Kaplan-Meier survival curves. Left panel, survival analysis based on LNR. Right panel, survival analysis based on the total number of examined LN. LN, lymph node; LNR, lymph node ratio. Multivariate analysis of factors predictive of poor overall survival LNR, lymph node ratio.

Discussion

LN involvement remains one of the most important factors for predicating survival of patients with resection of pancreatic cancer [5,10]. However, both LN status and the numbers of examined LNs are imperfect as the sole predictor. LNR not only provides information regarding the number of positive LNs but also gives an estimate of the adequacy of LNs obtained [9], which is a significant modifier of the effect of LN status and the numbers of examined LNs on survival of patients with resected cancer [11]. LNR has been identified as a tool to predict outcome in cancers of the esophagus [12], stomach [13], colon [14], and ampulla of Vater [15]. However, the association of LNR and overall survival in pancreatic cancer has not been well defined. We showed that LNR is negatively correlated with the overall survival with a cutoff value of 0.2. There is no consensus on the best cutoff value for LNR. Pawlik and colleagues used categories of LNR <0.2, 0.4, and >0.4 [16], while House et al. used 0.18 as a cutoff value [17]. Ashfaq et al. indicated that LNR cutoff of 0.1 was statistically significant for survival discrimination [9]. Our study demonstrated that patients with LNR >0.2 displayed poor prognosis, as reported by previous studies [6,7]. In addition, we evaluated the prognostic role of examined LNs, which indicated that total number of examined LNs ≥12 was potentially associated with improved survival. Several studies have reported the link between longer survival and total number of examined LNs [18,19]. Our study might also indicate that standard lymphadenectomy is enough, because the mean number of LNs resected in patients with pancreatic cancer who underwent standard lymphadenectomy in the randomized controlled trials (RCTs) was 13 to 17 [20-22]. Extended lymphadenectomy increases the total number of examined LNs, but there are no significant differences in the overall survival between patients who underwent pancreatic cancer surgery with extended lymphadenectomy and those who underwent operation with standard lymphadenectomy [23,24]. On the contrary, extended lymphadenectomy may increase postoperative morbidities and mortalities and decrease quality of life [24,25]. Although there was a debate on the value of extended lymphadenectomy in the past, the ideas are beginning to converge. Unnecessary extended lymphadenectomy should be avoided, which has been recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Pancreatic Adenocarcinoma Version 1, 2014. Both the LN status and the LNR are influenced by the total LN harvested [10]. Valsangkar and colleagues analyzed 14,907 patients in a national database and 902 patients treated at a single large institution, which showed that a minimum of 13 to 16 LNs must be examined to accurately predict survival [10]. The mean number of the total examined LN was 8.2 ± 6.1 in our study, which might not do full justice to the prognostic value of LNR. Nevertheless, a moderate number (6 to 12 LNs) of the total examined LN could partly predict survival [10]. What we need to emphasize is that the retrieval of the lymph nodes not only depends on the scope of the lymphadenectomy but also depends on the seriousness of the pathologist. Only surgeons and pathologists cooperated closely may accurately evaluate the value of LNR.

Conclusions

The present study demonstrated that LNR >0.2 was an independent adverse prognostic factor, which is powerful and useful for prognostic assessment for pancreatic cancer.
  25 in total

1.  Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.

Authors:  S M Robinson; A Rahman; B Haugk; J J French; D M Manas; B C Jaques; R M Charnley; S A White
Journal:  Eur J Surg Oncol       Date:  2012-02-07       Impact factor: 4.424

2.  Pattern analysis of lymph node metastasis and the prognostic importance of number of metastatic nodes in ampullary adenocarcinoma.

Authors:  Jae Hoon Lee; Kyeong Geun Lee; Tae Kyung Ha; Young Jin Jun; Seung Sam Paik; Hwon Kyum Park; Kwang Soo Lee
Journal:  Am Surg       Date:  2011-03       Impact factor: 0.688

3.  Extended lymphadenectomy in pancreatic cancer is crucial.

Authors:  Tsutomu Fujii
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

4.  Revisiting the concept of lymph node metastases of pancreatic head cancer: number of metastatic lymph nodes and lymph node ratio according to N stage.

Authors:  Mee Joo Kang; Jin-Young Jang; Ye Rim Chang; Wooil Kwon; Woohyun Jung; Sun-Whe Kim
Journal:  Ann Surg Oncol       Date:  2014-01-14       Impact factor: 5.344

5.  An interactive Bayesian model for prediction of lymph node ratio and survival in pancreatic cancer patients.

Authors:  Brian J Smith; James J Mezhir
Journal:  J Am Med Inform Assoc       Date:  2014-01-20       Impact factor: 4.497

6.  Lymph node ratio as a quality and prognostic indicator in stage III colon cancer.

Authors:  Steven L Chen; Scott R Steele; John Eberhardt; Kangmin Zhu; Anton Bilchik; Alexander Stojadinovic
Journal:  Ann Surg       Date:  2011-01       Impact factor: 12.969

7.  N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.

Authors:  Nakul P Valsangkar; Devon M Bush; James S Michaelson; Cristina R Ferrone; Jennifer A Wargo; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2012-12-11       Impact factor: 3.452

8.  The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer.

Authors:  Minia Hellan; Can-Lan Sun; Avo Artinyan; Pablo Mojica-Manosa; Smita Bhatia; Joshua D I Ellenhorn; Joseph Kim
Journal:  Pancreas       Date:  2008-07       Impact factor: 3.327

9.  Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas.

Authors:  Murray F Brennan; Michael W Kattan; David Klimstra; Kevin Conlon
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

10.  Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.

Authors:  Charles J Yeo; John L Cameron; Keith D Lillemoe; Taylor A Sohn; Kurtis A Campbell; Patricia K Sauter; JoAnn Coleman; Ross A Abrams; Ralph H Hruban
Journal:  Ann Surg       Date:  2002-09       Impact factor: 12.969

View more
  19 in total

1.  Metastatic lymph node ratio and Lauren classification are independent prognostic markers for survival rates of patients with gastric cancer.

Authors:  Huan Wang; Xiao-Ming Xing; Lei-Na Ma; Lian Liu; Jing Hao; Ling-Xin Feng; Zhuang Yu
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

2.  Prognostic Value of Metastatic Lymph Node Ratio in Pancreatic Cancer.

Authors:  Can A Karaca; Ahmet Coker
Journal:  Indian J Surg Oncol       Date:  2018-10-26

3.  Clinicopathologic and survival analysis of resected ampullary adenocarcinoma.

Authors:  Matthew P Doepker; Zachary J Thompson; Barbara A Centeno; Richard D Kim; Joyce Wong; Pamela J Hodul
Journal:  J Surg Oncol       Date:  2016-05-09       Impact factor: 3.454

4.  Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy.

Authors:  Paolo Borghetti; Fernando Barbera; Marco Lorenzo Bonù; Francesca Trevisan; Stefano Ciccarelli; Paola Vitali; Marta Maddalo; Luca Triggiani; Nadia Pasinetti; Sara Pedretti; Bartolomea Bonetti; Gianluca Pariscenti; Andrea Tironi; Alberto Caprioli; Michela Buglione; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2016-05-26       Impact factor: 3.469

Review 5.  A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma.

Authors:  M Elshaer; G Gravante; M Kosmin; A Riaz; A Al-Bahrani
Journal:  Ann R Coll Surg Engl       Date:  2016-11-21       Impact factor: 1.891

6.  Laparoscopic versus open pancreaticoduodenectomy for pancreatic adenocarcinoma: long-term results at a single institution.

Authors:  John A Stauffer; Alessandro Coppola; Diego Villacreses; Kabir Mody; Elizabeth Johnson; Zhuo Li; Horacio J Asbun
Journal:  Surg Endosc       Date:  2016-09-07       Impact factor: 4.584

7.  Lymph node ratio is a prognostic factor for non-small cell lung cancer.

Authors:  Guangyuan Sun; Lei Xue; Mingdong Wang; Xuewei Zhao
Journal:  Oncotarget       Date:  2015-10-20

8.  The Role of Fibroblasts in Pancreatic Cancer: Extracellular Matrix Versus Paracrine Factors.

Authors:  Louisa Bolm; Simon Cigolla; Uwe A Wittel; Ulrich T Hopt; Tobias Keck; Dirk Rades; Peter Bronsert; Ulrich Friedrich Wellner
Journal:  Transl Oncol       Date:  2017-06-26       Impact factor: 4.243

9.  Score for the Overall Survival Probability of Patients With Pancreatic Adenocarcinoma of the Body and Tail After Surgery: A Novel Nomogram-Based Risk Assessment.

Authors:  Chaobin He; Shuxin Sun; Yu Zhang; Xiaojun Lin; Shengping Li
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

10.  Comparison of prognostic prediction between nomogram based on lymph node ratio and AJCC 8th staging system for patients with resected pancreatic head carcinoma: a SEER analysis.

Authors:  Ning Pu; Jianang Li; Yaolin Xu; Wanling Lee; Yuan Fang; Xu Han; Guochao Zhao; Lei Zhang; Abulimiti Nuerxiati; Hanlin Yin; Wenchuan Wu; Wenhui Lou
Journal:  Cancer Manag Res       Date:  2018-02-05       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.